| Title : Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease - Neumann_2021_BMC.Neurol_21_422 |
| Author(s) : Neumann S , Taylor J , Bamford A , Metcalfe C , Gaunt DM , Whone A , Steeds D , Emmett SR , Hollingworth W , Ben-Shlomo Y , Henderson EJ |
| Ref : BMC Neurol , 21 :422 , 2021 |
| Abstract : |
| PubMedSearch : Neumann_2021_BMC.Neurol_21_422 |
| PubMedID: 34715821 |
| Title : The minimum clinically important difference (MCID) for a falls intervention in Parkinson's: A delphi study - Henderson_2019_Parkinsonism.Relat.Disord_61_106 |
| Author(s) : Henderson EJ , Morgan GS , Amin J , Gaunt DM , Ben-Shlomo Y |
| Ref : Parkinsonism Relat Disord , 61 :106 , 2019 |
| Abstract : |
| PubMedSearch : Henderson_2019_Parkinsonism.Relat.Disord_61_106 |
| PubMedID: 30455158 |
| Title : Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial - Henderson_2016_Lancet.Neurol_15_249 |
| Author(s) : Henderson EJ , Lord SR , Brodie MA , Gaunt DM , Lawrence AD , Close JC , Whone AL , Ben-Shlomo Y |
| Ref : Lancet Neurol , 15 :249 , 2016 |
| Abstract : |
| PubMedSearch : Henderson_2016_Lancet.Neurol_15_249 |
| PubMedID: 26795874 |
| Title : The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen - Henderson_2013_BMC.Neurol_13_188 |
| Author(s) : Henderson EJ , Lord SR , Close JC , Lawrence AD , Whone A , Ben-Shlomo Y |
| Ref : BMC Neurol , 13 :188 , 2013 |
| Abstract : |
| PubMedSearch : Henderson_2013_BMC.Neurol_13_188 |
| PubMedID: 24299497 |